The Latest Advancements in Glaucoma Treatments and Ophthalmology

January is Glaucoma Awareness Month, dedicated to raising awareness about this “silent thief of sight,” a condition that often progresses without symptoms and can lead to permanent vision loss. Affecting over 2.7 million Americans over age 40, glaucoma is a major public health issue. While incurable, advances in treatment are offering more personalized care, including new detection methods, medications, and minimally invasive surgeries. Biocom California member companies are at the forefront of these innovations, driving progress in glaucoma and ophthalmology therapies to improve patient outcomes and reduce the impact of this disease.

Glaukos Corporation

Glaukos Corporation, a leader in Micro-Invasive Glaucoma Surgery (MIGS), has transformed glaucoma treatment with its iStent system, which is widely used in conjunction with cataract surgery to lower intraocular pressure. The company recently shared promising results from a 36-month Phase 3 clinical trial for its FDA-approved iDose TR implant, which showed sustained efficacy in reducing intraocular pressure in glaucoma patients. This innovative, minimally invasive treatment not only addresses the challenge of medication non-adherence but has also driven an 18.7% revenue growth over the past year. As part of its growth strategy, Glaukos is advancing its product pipeline with exciting new innovations like iDose TREX. Additionally, the acquisition of Avedro, known for its Corneal Crosslinking devices, strengthens Glaukos’ position in the ophthalmic care market and reflects its commitment to expanding its MIGS offerings and transforming the treatment of chronic eye diseases.

Novoron Bioscience

Novoron Bioscience is advancing glaucoma and ophthalmology treatments with its promising therapies, including NOVO-118, which is currently undergoing clinical trials for ocular hypertension, a condition linked to glaucoma. The company is part of a broader effort involving over 60 companies working to develop new treatments for ocular hypertension. In addition to NOVO-118, Novoron is exploring other therapies like AGN-193408, DE-126, and ONL1204, all at various stages of development. These innovations demonstrate Novoron’s commitment to improving glaucoma care and addressing unmet patient needs in the field.

Novartis

Novartis has made significant strides in glaucoma and ophthalmology over the last year through several key advancements. The company has expanded its partnership with Google Health to utilize AI and machine learning for earlier, more accurate glaucoma detection, focusing on improving diagnostic tools using OCT images. Additionally, Novartis continues to enhance its femtosecond laser platform, LenSx, for more precise glaucoma surgeries. Their glaucoma treatment Xalocom remains a cornerstone of combination therapy, while ongoing research into gene therapies for glaucoma-related genetic mutations shows promise for future treatments. Novartis has also advanced digital health solutions, integrating telemedicine and big data for improved remote monitoring and patient management, further advancing their commitment to innovation in ophthalmology.

ViaLase

ViaLase, an innovative medical technology company based in Aliso Viejo, has achieved several key milestones in advancing its femtosecond laser technology for glaucoma treatment. Last December, they announced a research partnership with the John A. Moran Eye Center at the University of Utah to explore aqueous outflow dynamics and optimize treatment efficacy. In July 2024, ViaLase received CE Mark approval for its laser system, enabling its use in European markets. Additionally, last April, ViaLase closed a $40 million Series C financing round to support clinical, regulatory, and commercial progress. These efforts highlight ViaLase’s commitment to innovating glaucoma care with minimally invasive solutions.